A Timing Effect of 17-β Estradiol on Atherosclerotic Lesion Development in Female ApoE

Obialunanma V Ebenebe, Zoe Ashley, Jeffrey R Erickson, Alison K Heather

Open access · goldAbstract read

In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.2field-weighted citation impact, top 39% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

S-nitrosylation of cardiac myocyte proteins may underlie sex differences in cardiac disease.Frontiers in physiology · 2025
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Obialunanma V EbenebeDepartment of Physiology and Heart Otago, School of Biomedical Sciences, University of Otago, Dunedin 9054, New Zealand.

Zoe AshleyDepartment of Physiology and Heart Otago, School of Biomedical Sciences, University of Otago, Dunedin 9054, New Zealand.ORCID 0000-0001-8563-5600

Jeffrey R EricksonDepartment of Physiology and Heart Otago, School of Biomedical Sciences, University of Otago, Dunedin 9054, New Zealand.

Alison K HeatherDepartment of Physiology and Heart Otago, School of Biomedical Sciences, University of Otago, Dunedin 9054, New Zealand.

University of Otago · NZJohns Hopkins University · US

Funding

Health Research Council of New Zealand 15/331National Heart Foundation of New Zealand 1772University of Otago Research Grant ORG0119-0320

6 · The paper itself

Abstract

Differences in size or composition of existing plaques at the initiation of estrogen (E2) therapy may underpin evidence of increased risk of atherosclerosis-associated clinical sequelae. We investigated whether E2 had divergent effects on actively-growing versus established-advanced atherosclerotic lesions. Eight weeks of subcutaneous bi-weekly injections of 3 µg/g 17β-estradiol (

Indexed as

AnimalsAortaApolipoproteins EAtherosclerosisCholesterolDisease Models, AnimalEstradiolEstrogensFemaleFibrosisLipidsMiceMice, Inbred C57BLMice, KnockoutTime FactorsVascular CalcificationApolipoproteins ECholesterolEstradiolEstrogensLipidsatherosclerosiscalcificationestrogen therapyfibrosisintimal thickeningmenopause

Identifiers

PMID32630298

DOI10.3390/ijms21134710

PMCPMC7369926

OpenAlexW3038970540

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.